Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
– Positive interim topline data for DUNE trial of sevasemten in Becker – – Expanded Phase 2 LYNX trial of sevasemten in Duchenne – – Anticipated to overenroll Phase 2 FOX trial in Duchenne boys previously treated with gene therapy – – Initiated Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive HCM – BOULDER, Colo., May 09, 2024 BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights. "2024 is off to a great start with tremendous progress on our skeletal and cardiac muscle programs," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. "Most recently, we initiated our Phase 2 CIRRUS-HCM trial of EDG-7500 and announced positive 2-year topline data from our ARCH open label trial in Becker. We expect significant catalysts on our programs throughout this year including data from the CANYON an
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run [Seeking Alpha]Seeking Alpha
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024Business Wire
- Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire
- Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 5/9/24 - Beat
EWTX
Sec Filings
- 5/10/24 - Form 8-K
- 5/10/24 - Form S-3ASR
- 5/9/24 - Form S-8
- EWTX's page on the SEC website